Lingyi Biotechnology

Explore the latest insights on Lingyi Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lingyi Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Lingyi Biotechnology and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lingyi Biotechnology's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery
CompanyDeals

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery

METiS TechBio (HKG: 7666), an innovative AI drug delivery company, announced a strategic collaboration with Eli Lilly and Company (NYSE: LLY) focused on the research and discovery of novel lipid…

Sanofi Breaks Ground on Next‑Generation Insulin Manufacturing Facility at Frankfurt BioCampus – Full API Production Planned for 2032

Sanofi Breaks Ground on Next‑Generation Insulin Manufacturing Facility at Frankfurt BioCampus – Full API Production Planned for 2032

Hansoh Pharma Strikes Second ADC Licensing Deal with Roche – USD 400 Million Upfront, Over USD 15 Billion in Potential Milestones

Hansoh Pharma Strikes Second ADC Licensing Deal with Roche – USD 400 Million Upfront, Over USD 15 Billion in Potential Milestones

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development
CompanyDeals

Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development

Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement
CompanyDeals

Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement

CompanyDrug

Lingyi Biotechnology’s Gene Therapy Candidate LY-M001 Gets FDA Green Light for Gaucher’s Disease

CompanyDeals

Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline